Log in
IA

INVESTOR AB

INVESTOR AB · Investor
1Y performance ⓘ
+6%
AUM (13F)
$15.1B
# of Holdings
10
3Y performance ⓘ
+57%
vs S&P 500 ⓘ
−15%
Updated
Mar 31

INVESTOR AB's INVESTOR AB holds 10 U.S.-equity positions worth $15.1B (SEC 13F, Q1 2026). Top positions: AstraZeneca PLC 67.3%, Nasdaq, Inc. Common Stock 32.6%, MediWound Ltd. 0.1%. 13F-replication return is +57% over 3 years (-15 pts vs the S&P 500) — a replicated, non-audited figure.

Holdings

Stock% of portfolio SharesValue Latest activityAvg buy price Current priceDate
AZN AstraZeneca PLC 67.3% 51.6M $10.2B NEW (+51.6M) $197.22 $176.43 (−11%) 2026-03-31
NDAQ Nasdaq, Inc. Common Stock 32.6% 58.4M $4.9B $54.67 $82.61 (+51%) 2026-03-31
MDWD MediWound Ltd. 0.1% 872K $14M $18.06 $13.96 (−23%) 2026-03-31
CLBT Cellebrite DI Ltd. Class A Ordinary Shares 0.0% 55K $758K NEW (+55K) $22.03 $12.42 (−44%) 2026-03-31
COHR Coherent Corp. 0.0% 3K $715K ▼ 50% (−3K) $60.62 $425.48 (+602%) 2026-03-31
KYIV Kyivstar Group Ltd. Common Shares 0.0% 59K $601K NEW (+59K) $12.50 $14.02 (+12%) 2026-03-31
VZ Verizon Communications 0.0% 11K $567K NEW (+11K) $50.20 $45.36 (−10%) 2026-03-31
CRSR Corsair Gaming, Inc. Common Stock 0.0% 100K $553K ▼ 20% (−25K) $5.94 $9.24 (+56%) 2026-03-31
WHR Whirlpool Corp. 0.0% 5K $253K ▲ 27% (+1K) $90.13 $36.57 (−59%) 2026-03-31
BMRN BioMarin Pharmaceuticals Inc 0.0% 4K $209K $70.69 $55.90 (−21%) 2026-03-31
Related
AZN stockNDAQ stockMDWD stockCLBT stockAll hedge funds
FAQ

What are INVESTOR AB's largest holdings?

As of the latest 13F: AstraZeneca PLC 67.3%, Nasdaq, Inc. Common Stock 32.6%, MediWound Ltd. 0.1%, Cellebrite DI Ltd. Class A Ordinary Shares 0.0%, Coherent Corp. 0.0%.

How big is INVESTOR AB's 13F portfolio?

$15.1B across 10 disclosed U.S.-equity positions.

What is INVESTOR AB's 3-year performance?

+57% (13F-replication, price return), -15 pts vs the S&P 500. Not an audited fund return.

Where does this data come from?

U.S. SEC Form 13F-HR institutional holdings filings.

Sourced from SEC Form 13F-HR filings · Not investment advice
SEC EDGAR 13F
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.

Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.